ArticleDrug design, development and therapy2025
Development of Chitosan-Polyacrylic Acid Complex Systems for Enhanced Oral Delivery of
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Enhancing Antimicrobial Efficacy: The Role of Metal Complexation in Chitosan-Based Antimicrobial Agents.Applied biochemistry and biotechnology · 2026Review
- Polydopamine cross-linked Bifidobacterium single cell core-shell system with multi-target regulation to alleviate constipation in mice.Archives of microbiology · 2026Article
- Antimicrobial, anticancer activities and molecular docking of eco-friendly chitosan nanocapsule loaded with biosynthesized titanium nanoparticles byFrontiers in microbiology · 2026Article
- Survival Behavior ofFood science & nutrition · 2025Article
- The relationship between vaginal and endometrial microbiota and the outcome of Frozen-Thawed embryo transfer during hormone replacement cycles.BMC microbiology · 2025Article
- In vitro antibacterial efficacy of a novel chicken-derived Bacillus subtilis GX15 strain and its protective mechanisms in mice challenged by Salmonella enterica serovar typhymurium.BMC microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The beneficial effects of probiotics are encountered by their low viability in gastrointestinal conditions and their insufficient stability during manufacturing, throughut the gastrointestinal transit, and storage. Therefore, novel systems are highly required to improve probiotics delivery. Methods: In this study, Lactobacillus gasseri (L), Bifidobacterium bifidum (B), and a combination of L+B were encapsulated in chitosan (CS)-polyacrylic acid (PAA) complex systems (CS-PAA). The CS-PAA systems were analysed on basis of morphology, size, and zeta potential. The loaded CS-PAA systems were evaluated for their morphology, particle size, zetapotential, vaiability in both simulated gastroic and intestinal fluids, and stability at 4°C storage temparature. Moreover, the antibiofilm activity of the probiotics-loaded systems were evaluated againt Campylobacter jejuni, Pseudomonas aeruginosa and Escherichia coli. Results: Probiotic strains were successfully incorporated into the porous structures of the CS-PAA systems, either individually or in combination. The Loaded L, B, and L+B showed higher particle size than the unloaded particles and excellent viability in simulated gastric and intestinal fluids, where the free probiotic species were undetected. Additionally the loaded probiotic exhibited an anti-biofilm effect at 0.5 mg/mL concentration level. Conclusion: The CS-PAA complexes demonstrate a promising mechanism for the effective delivery of incorporated probiotics. The probiotics exhibited high viability and maintain stability under physiological conditions, and showed a remarkable anti-biofilm activity. These characteristics suggest that CS-PAA could serve as an alternative system for probiotics, enhancing gut microbiota health and offering a robust protection against microbial pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.